Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Daniel Ciznadija"'
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c2efa1fb2eca5731e15fb0928e1e7b7
https://doi.org/10.1158/1535-7163.c.6543438.v1
https://doi.org/10.1158/1535-7163.c.6543438.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Figure from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f6636bc7fd14949c096b587e72af567
https://doi.org/10.1158/1535-7163.22522569.v1
https://doi.org/10.1158/1535-7163.22522569.v1
Autor:
Simon S. McDade, Ultan McDermott, Daniel B. Longley, Mathew Garnett, Lodewyk Wessels, David A. Tice, Amy Wesa, Ido Sloma, Daniel Ciznadija, Syd Barthorpe, Aikaterini Chatzipli, Vivek Iyer, Magali Michaut, Lewis Gallagher, Jess Bateson, Jamie Young, Jochen Prehn, Katherine McAllister, Christopher McCann, Andrea Lees, Stacey Price, Nyree Crawford, Mark Wappett, Vera Grinkevitch
Supplementary Data from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a65e018c5371d1a9a5d2dd985a27fdf8
https://doi.org/10.1158/1535-7163.22522572.v1
https://doi.org/10.1158/1535-7163.22522572.v1
Autor:
Gilad Silberberg, Brandon Walling, Amy Wesa, Alessandra Audia, Ido Sloma, Yi Zeng, Guanghui Han, Jia Tang, Paige Pammer, A’ishah Bakayoko, Xuan Ren, Daniel Ciznadija, Bandana Vishwakarma, Yaron Mosesson, Marianna Zipeto, Michael Ritchie
Despite considerable progress made in improving therapeutic strategies, the overall survival for patients diagnosed with various cancer types remains low. Further, patients often cycle through multiple therapeutic options before finding an effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c707f615650caa1ede4c0ebad5dba96
https://doi.org/10.1101/2022.06.14.495846
https://doi.org/10.1101/2022.06.14.495846